The Executive Committee on Global Health and Human Security has compiled draft proposals to further promote pharmaceutical and medical device regulatory harmonization in Asia. While the proposals revolve around initiatives for two main pillars - building clinical trial networks and…
HOME > TOP STORIES
TOP STORIES
-
BUSINESS Sanofi Japan Introduces 2-Week-Rule before Getting Back to Full Operations after COVID-19 Emergency Lift
May 29, 2020
-
ACADEMIA Nagasaki Univ. to Launch Clinical Trial for Nelfinavir for COVID-19
May 28, 2020
-
BUSINESS Drug Makers Exploring “New Normal” in Post-COVID-19; Takeda Plans Major Changes
May 28, 2020
-
BUSINESS Japan SGLT2 Inhibitor Market Hits 100 Billion Yen after Weak Start: Jiho Estimate
May 27, 2020
-
REGULATORY Japan Drops May-End Goal for Avigan’s COVID-19 Approval
May 27, 2020
-
ACADEMIA Discontinued HIV Med Nelfinavir Hits Limelight as Potential COVID-19 Treatment
May 26, 2020
-
REGULATORY Japan Govt to Give Up on May-End Goal for Avigan Approval
May 26, 2020
-
REGULATORY MSD’s 9-Valent HPV Vaccine Now in Line for June Approval; Eyes on Its Possible Inclusion in National Immunization Program
May 25, 2020
-
BUSINESS GSK Japan Looking to Develop Otilimab for COVID-19; President Stresses Efforts on Vaccines, Disease Management Too
May 22, 2020
-
ACADEMIA Avigan Interim Analysis Not Intended to Determine Efficacy, Research Sponsor Says on Reports
May 21, 2020
-
REGULATORY MHLW Adds Veklury in Updated COVID-19 Treatment Guide
May 20, 2020
-
BUSINESS Nichi-Iko Launches Another Recall, Now Pulling 8 More APIs/9 Products
May 19, 2020
-
REGULATORY Check Latest Info and Make Careful Decision on Veklury Use: PMDA Review Report
May 19, 2020
-
BUSINESS Many Drug Makers Continue Work-from-Home, Voluntary Visit Bans after Govt Partially Lifts COVID-19 Emergency
May 18, 2020
-
BUSINESS Takeda Revving Up Efforts to Retool Japan Sales System as It Prepares for “New Normal” Post COVID-19
May 18, 2020
-
REGULATORY Japan’s First Humira Biosimilar Could Hit Market as Early as November
May 15, 2020
-
REGULATORY Japan Poised to Quickly Approve Futhan, Actemra, Ivermectin for COVID-19 If Effective: Abe
May 15, 2020
-
REGULATORY Chuikyo Members Frown on Zolgensma’s Sakigake Premium; Topic Up for 2022 Pricing Debate
May 14, 2020
-
BUSINESS Eisai Resurrects Eritoran as Potential COVID-19 Treatment, Eyes Trial Launch Next Month
May 14, 2020
-
BUSINESS Takeda Exec Says Plasma Alliance Could Start Clinical Trial for Unbranded Therapy in July
May 14, 2020
ページ
When Jiho surveyed drug makers on the non-sales criteria they use to evaluate reps’ performance, it received a variety of…
Nearly a year after the introduction of the Ministry of Health, Labor and Welfare’s (MHLW) drug promotion guidelines in April…
Advancements in modified oligonucleotide technologies has been the key driver behind a spate of approvals in the oligonucleotide therapeutics space…
Japan’s key reimbursement policy panel on December 20 approved an outline of its FY2020 drug pricing reform next April, with…
The Ministry of Health, Labor and Welfare (MHLW) on November 27 added to the NHI price list Japan’s first biosimilars of Avastin (bevacizumab), Nesp (darbepoetin alfa), and Forteo (teriparatide). The NHI prices of first biosimilars are set at 70% of…
A total of 51 new drugs joined the NHI price list in 2019, which are expected to generate combined peak sales of 373 billion yen, according to Jiho’s tally of data submitted to a key reimbursement policy panel. The relatively…
Some seven years in the making, Japan’s Ministry of Health, Labor and Welfare (MHLW) finally rolled out a cost-effectiveness assessment…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…
Look into the heart of every successful company, the businesses that have made a real impact on the world, and you’ll notice they all share a common trait.The people. But not just any people, as Jim Collins famously said…“People are…